Mentioned in ?
References in periodicals archive ?
The report analyzes the markets for factor XIII concentrates, fibrinogen concentrates, albumins, antithrombins and prothrombin complex concentrates in the US, the top five countries of Europe (the UK, Germany, France, Italy and Spain), and Japan.
Lower limits of detection were 1-2% for the intrinsic factors (VIII, IX, XI, and XII), 5-7% for the extrinsic factors (II, V, VII, and X), and 10% for proteins C and S and antithrombin activity.
6) Furthermore, patients who have antithrombin, protein C or protein S deficiencies, multiple inherited risk factors, or homozygosity for Factor V Leiden, were found to have increased risk of recurrence compared with patients without them.
The company's lead product, ATryn is the first and only plasma-free antithrombin concentrate.
To make the drug, scientists from GTC put modified DNA, that is recombinant DNA, or rDNA, for the human antithrombin protein into single-cell embryos of goats.
Two enzymatic assay principles exist for the determination of antithrombin activity, both using a chromogenic substrate.
1) These scaled-down versions of the traditional heparin chain have the specific pentasaccharide sequence that is necessary to bind with antithrombin.
The company's lead product, ATryn[R] Antithrombin (Recombinant), is the first and only plasma-free antithrombin concentrate.
Antithrombin is a blood protein that regulates clotting.
Additional study of the other endogenous anticoagulants, including antithrombin III and activated protein C (in the absence of heparin), may be warranted, they concluded.